ITI-1284 20 mg for generalized anxiety disorder

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 28 Jun 2024: Trial registered, NCT06480383
  2. 5 Aug 2024: Trial started, NCT06480383

The trials

NCT06480383: Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder

State
Under way
Phase
Phase 2
People
705 planned
Started
5 Aug 2024
Primary completion
16 Mar 2027
Arms
ITI-1284 20 mg
Results
None posted
  1. 28 Jun 2024: Trial registered
  2. 5 Aug 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.